DEC 18, 2019 8:32 AM PST

Germs don't stand a chance with new AI-powered diagnostic platform

WRITTEN BY: Tara Fernandez

We are steadily losing our edge in the war against infectious bacteria. A huge surge in antibiotic resistance is threatening healthcare and agricultural industries. Annually, 2.8 million people became infected with antibiotic-resistant microbes in the U.S. alone.

Since penicillin, our arsenal of antimicrobial drugs has grown, only to be swiftly overpowered by selective pressure and DNA mutations that give bacteria the upper hand.

In 2015, for instance, the antibiotic Ceftazidime-avibactam was approved by the Food and Drug Administration to treat hospital-acquired pneumonia and other multi-drug resistant infections. Featured as a reserve on the World Health Organization’s List of Essential Medicines, healthcare experts were hopeful that this medication would function as a last resort to resist superbugs.

Disastrously, in the same year of its release, the gut bacteria Klebsiella pneumoniae was found to have acquired resistance, making it a potentially deadly hospital-acquired infection threat.

On the verge of a global medical crisis, Niamh O’Hara, Co-founder and CEO of the biotech start-up, Biotia, saw an opportunity. Using next-generation DNA sequencing and software powered by artificial intelligence, O’Hara and colleagues at Weill Cornell Medicine and Cornell Tech have developed a robust digital platform for diagnosing and controlling microbial infections.

 

 

As O’Hara explains, the method most hospitals use to identify pathogens dates back to the 1800s: a process called culturing. Here, bacteria from patient samples are provided with nutrients and optimal growth conditions and allowed to multiply so that a microbiologist can establish their origin. This low-tech system is prone to failure and provides only limited information regarding how successfully the infection can be treated with antibiotics.

Biotia’s system, which recently raised $2.4 million in investment funding, genetically profiles bacteria with unparalleled precision and uses powerful computing systems to predict the likelihood of developing resistance. The artificial intelligence-driven software, known as Chelsea™, scans a genetic database of over 16,000 bacteria, viruses, fungi, and parasites, providing a complete report on exactly what the offending pathogen is and predicts its drug resistance.

Working closely with hospitals during this developmental phase, Biotia’s founders envision a future where healthcare providers can provide rapid, targeted, life-saving treatments and where hospital-acquired infections become a thing of the past.

 

Sources: Cornell Tech, Biotia.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 06, 2020
Clinical & Molecular DX
Device Diagnoses Breast Cancer in 60 Minutes
AUG 06, 2020
Device Diagnoses Breast Cancer in 60 Minutes
Researchers have created a point-of-care device that can provide diagnostic results for breast cancer in under an hour. ...
AUG 17, 2020
Microbiology
Ingestible Bacteria-Catcher Could Act as a Diagnostic Tool
AUG 17, 2020
Ingestible Bacteria-Catcher Could Act as a Diagnostic Tool
Microbes in our gastrointestinal tract may not only be closely linked to our health, but they may also be useful as a di ...
AUG 20, 2020
Clinical & Molecular DX
Machines Learn the Difference Between Autism and Schizophrenia
AUG 20, 2020
Machines Learn the Difference Between Autism and Schizophrenia
 
SEP 03, 2020
Cell & Molecular Biology
Diagnosing Non-Celiac Gluten Sensitivity
SEP 03, 2020
Diagnosing Non-Celiac Gluten Sensitivity
Many clinicians once thought that only celiac disease caused gluten intolerance. But some people without it report gastr ...
SEP 21, 2020
Clinical & Molecular DX
Smart Wearable Patch Signals Trouble Following Traumatic Injury
SEP 21, 2020
Smart Wearable Patch Signals Trouble Following Traumatic Injury
An ambulance pulls up to the site of a car accident, sirens blazing. Paramedics assess the crash victims, looking for si ...
OCT 13, 2020
Cardiology
A Kidney Toxin Could Act as a Biomarker for Cardiovascular Risk
OCT 13, 2020
A Kidney Toxin Could Act as a Biomarker for Cardiovascular Risk
Biomarkers have taken the diagnostic field by storm over the past decade. The search for stable, easy to access indicato ...
Loading Comments...